SAR 1118 Demonstrates Encouraging Results In Phase 2 Study Of Dry Eye Disease
SARcode Corporation presented data for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function as compared to placebo...